July 15, 2026
Valitor to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

May 13, 2026
Valitor to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 4, 2026
Valitor Presents Preclinical Data Demonstrating Superior Durability with Six-month Treatment Protocol of VLTR-559 to Treat Wet AMD

April 9, 2026
Valitor to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 7, 2026
Valitor Announces Oral Presentation at the Upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting

November 20, 2025
Valitor Announces Upcoming Presentation at the 15th Annual Ophthalmology Innovation Summit (OIS)

October 20, 2025
Valitor Presents Preclinical Data Demonstrating VLTR-559 Achieves Superior Durability and Sustained Anti-VEGF Activity with a Favorable Safety Profile as a Treatment for Wet AMD

October 17, 2025
Valitor Appoints Biotech and Ophthalmic Industry Veteran Gregory D. Kunst as Chief Executive Officer

October 6, 2025
Valitor Announces Upcoming Presentation at the Eyecelerator Conference Hosted in Conjunction with the American Academy of Ophthalmology (AAO) 2025 Annual Meeting

September 4, 2025
Valitor Presents New Preclinical Data Demonstrating VLTR-559, an Anti-VEGF Drug Candidate for Wet AMD with a Twice-Yearly “Treat-and-Release” Regimen, Exhibits Favorable Safety Profile Similar to Short-Acting Anti-VEGFs  

August 21, 2025
Valitor Announces Upcoming Presentations at the Ophthalmology Futures Retina Forum and Euretina Conference, Including New Data for its Long-Acting Anti-VEGF Drug Candidate for Wet AMD, VLTR-559

July 30, 2025
Valitor Highlights Three-fold Increase with VLTR-559 in Sustained Potency and Durability over Aflibercept in Preclinical Ocular Wet AMD Models

May 7, 2025
Valitor Presents Multiple Preclinical Datasets on the Potential of its Innovative Anti-VEGF Therapy Dosed Twice Yearly for Wet AMD at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 30, 2025
Valitor to Present on its Drug Candidate with Twice-Yearly Dosing for Wet AMD at the American Academy of Ophthalmology’s Eyecelerator Conference and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

August 12, 2024
Valitor to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

July 19, 2023
Valitor Expands Leadership Team with Appointment of Omkar Joshi, Ph.D. as Vice President of CMC

April 24, 2023
Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Vision and Ophthalmology Annual Meeting

April 10, 2023
Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting

March 23, 2023
Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting

December 01, 2022
Valitor Announces Presentation on Novel Anti-VEGF Antibody Conjugate and Multivalent Polymer Technology Platform at Upcoming Ophthalmology Innovation Source (OIS) Summit - Preclinical data support twice-yearly dosing in wet AMD -

October 05, 2022
Valitor Announces the Closing of its Series B Financing and Names Steven Lo as Chief Executive Officer